Skip to content
  • Job Openings
  • Contact Us
Freenome Holdings, Inc. logo
Main Menu
  • Our Science
  • Clinical Expertise
    • Our Studies
    • Our Publications
  • Our Company
    • About Our Company
    • Leadership
    • Partnerships
  • Newsroom
  • Careers
    • Our Work
    • Job Openings
Freenome Holdings, Inc. logo
Main Menu
  • Our Science
  • Clinical Expertise
    • Our Studies
    • Our Publications
  • Our Company
    • About Our Company
    • Leadership
    • Partnerships
  • Newsroom
  • Careers
    • Job Openings
  • Contact Us
  • View All Posters

Interception versus prevention in cancer screening in a Medicare population: Results from the CRC-MAPS model

Putcha G, Carroll LN, Chandra T, Piscitello A

Download
PrevOlderAdenoma detection improves clinical outcomes across adherence scenarios for a CRC screening blood test meeting CMS performance targets: Results from the CRC-MAPS model
NewerIdentification of predictive biomarkers for response of R/R DLBCL patients treated with loncastuximab tesirine using low-pass whole-genome cell-free DNA sequencing (cfDNA-WGS)Next
Categories
  • Presentations
  • Manuscripts

3300 Marina Boulevard
Brisbane, CA
94005

Contact Us

Privacy Policy

Terms of Use

Cookie Notice

Twitter X logo

©2025 Freenome Holdings, Inc. The following are registered trademarks of Freenome Holdings, Inc.: FREENOME®, PREEMPT CRC® and AI-EMERGE®. All rights reserved.

  • Services
  • About
  • Reviews
  • Why Us
  • Contact
  • Home
  • Services
  • About
  • Reviews
  • Why Us
  • Contact
  • Home